AstraZeneca announced this week the completion of the divestment of Imdur to China Medical System Holdings Ltd. and Tibet Rhodiola Pharmaceutical Holding Co.
AstraZeneca will receive $190 million for the global rights
outside of the U.S.
Imdur (isosorbide mononitrate) is used to prevent angina attacks. The medication dilates blood vessels. The wider blood vessels allow the blood to move through the body easily, reducing the load on the heart as it pumps. This helps prevent chest pain. It cannot help if an angina attack has already begun.
Angina, also known as angina pectoris, is usually caused by coronary artery disease. The pain occurs when the heart muscle is not receiving enough oxygen-rich blood. When the arteries are narrowed or blocked, the burning or squeezing chest pain may slowly increase or appear suddenly.
The extended-release Imdur tablets are generally prescribed to patients with coronary artery disease. Since its launch in Europe in 1985, Imdur has been marketed in more than 40 countries. Global sales reached $57 million in 2015.
AstraZeneca focuses on the discovery and development of prescription medications for respiratory, inflammation, autoimmune disease (RIA); cardiovascular and metabolic disease (CVMD) and cancer. Millions of patients worldwide use medications developed and commercialized by the biopharmaceutical company.
Alerts Sign-up